228 related articles for article (PubMed ID: 15608694)
1. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies.
Inoue S; MacFarlane M; Harper N; Wheat LM; Dyer MJ; Cohen GM
Cell Death Differ; 2004 Dec; 11 Suppl 2():S193-206. PubMed ID: 15608694
[TBL] [Abstract][Full Text] [Related]
2. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways.
Shankar S; Singh TR; Fandy TE; Luetrakul T; Ross DD; Srivastava RK
Int J Mol Med; 2005 Dec; 16(6):1125-38. PubMed ID: 16273296
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
Earel JK; VanOosten RL; Griffith TS
Cancer Res; 2006 Jan; 66(1):499-507. PubMed ID: 16397266
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia.
MacFarlane M; Harper N; Snowden RT; Dyer MJ; Barnett GA; Pringle JH; Cohen GM
Oncogene; 2002 Oct; 21(44):6809-18. PubMed ID: 12360407
[TBL] [Abstract][Full Text] [Related]
5. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1.
MacFarlane M; Inoue S; Kohlhaas SL; Majid A; Harper N; Kennedy DB; Dyer MJ; Cohen GM
Cell Death Differ; 2005 Jul; 12(7):773-82. PubMed ID: 15861184
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells.
Nakata S; Yoshida T; Horinaka M; Shiraishi T; Wakada M; Sakai T
Oncogene; 2004 Aug; 23(37):6261-71. PubMed ID: 15208660
[TBL] [Abstract][Full Text] [Related]
7. IG20 (MADD splice variant-5), a proapoptotic protein, interacts with DR4/DR5 and enhances TRAIL-induced apoptosis by increasing recruitment of FADD and caspase-8 to the DISC.
Ramaswamy M; Efimova EV; Martinez O; Mulherkar NU; Singh SP; Prabhakar BS
Oncogene; 2004 Aug; 23(36):6083-94. PubMed ID: 15208670
[TBL] [Abstract][Full Text] [Related]
8. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies.
MacFarlane M; Kohlhaas SL; Sutcliffe MJ; Dyer MJ; Cohen GM
Cancer Res; 2005 Dec; 65(24):11265-70. PubMed ID: 16357130
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors.
VanOosten RL; Earel JK; Griffith TS
Cancer Gene Ther; 2006 Jun; 13(6):628-32. PubMed ID: 16456549
[TBL] [Abstract][Full Text] [Related]
10. Casein kinase I attenuates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by regulating the recruitment of fas-associated death domain and procaspase-8 to the death-inducing signaling complex.
Izeradjene K; Douglas L; Delaney AB; Houghton JA
Cancer Res; 2004 Nov; 64(21):8036-44. PubMed ID: 15520213
[TBL] [Abstract][Full Text] [Related]
11. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
[TBL] [Abstract][Full Text] [Related]
12. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic Ras sensitizes normal human cells to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis.
Nesterov A; Nikrad M; Johnson T; Kraft AS
Cancer Res; 2004 Jun; 64(11):3922-7. PubMed ID: 15173003
[TBL] [Abstract][Full Text] [Related]
15. Regulation of the resistance to TRAIL-induced apoptosis as a new strategy for pancreatic cancer.
Mori T; Doi R; Toyoda E; Koizumi M; Ito D; Kami K; Kida A; Masui T; Kawaguchi Y; Fujimoto K
Surgery; 2005 Jul; 138(1):71-7. PubMed ID: 16003319
[TBL] [Abstract][Full Text] [Related]
16. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma.
Singh TR; Shankar S; Srivastava RK
Oncogene; 2005 Jul; 24(29):4609-23. PubMed ID: 15897906
[TBL] [Abstract][Full Text] [Related]
17. Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells.
Secchiero P; Tiribelli M; Barbarotto E; Celeghini C; Michelutti A; Masolini P; Fanin R; Zauli G
J Cell Physiol; 2005 Nov; 205(2):246-52. PubMed ID: 15887227
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
Mühlethaler-Mottet A; Flahaut M; Bourloud KB; Auderset K; Meier R; Joseph JM; Gross N
BMC Cancer; 2006 Aug; 6():214. PubMed ID: 16930472
[TBL] [Abstract][Full Text] [Related]
19. Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228).
Sutheesophon K; Nishimura N; Kobayashi Y; Furukawa Y; Kawano M; Itoh K; Kano Y; Ishii H; Furukawa Y
J Cell Physiol; 2005 May; 203(2):387-97. PubMed ID: 15515013
[TBL] [Abstract][Full Text] [Related]
20. Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts.
Vanoosten RL; Moore JM; Ludwig AT; Griffith TS
Mol Ther; 2005 Apr; 11(4):542-52. PubMed ID: 15771957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
